Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Clouston

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Pharmacological Research|March 28, 2015
Effect of resveratrol on experimental non-alcoholic steatohepatitisSara Heebøll, Karen Louise Thomsen, Andrew Clouston, et al.
Plos One|August 9, 2016
Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRITim G St Pierre, Michael J House, Sander J Bangma, et al.
Metabolism: Clinical and Experimental|September 25, 2017
Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitisMuralidhara Rao Maradana, Suman Kumar Yekollu, Bijun Zeng, et al.
British Journal of Pharmacology|June 26, 2019
Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammationZhixuan Loh, Rebecca L Fitzsimmons, Robert C Reid, et al.
Journal for Immunotherapy of Cancer|January 12, 2023
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, Keith Dredge, Darryn Bampton, et al.
Internal Medicine Journal|October 31, 2017
Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosisPreya J Patel, Xuan Banh, Leigh U Horsfall, et al.
Blood|August 5, 2010
An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammationKelli P A MacDonald, James S Palmer, Stephen Cronau, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2026
Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescenceHani Vu, Yuliangzi Sun, Zherui Xiong, et al.
Journal of Hepatology|October 10, 2025
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trialsCarolin Lackner, Annette S H Gouw, Venancio Avancini Ferreira Alves, et al.
Carcinogenesis|February 25, 2016
Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinomaLutz Krause, Katia Nones, Kelly A Loffler, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Pharmacological Research|March 28, 2015
Effect of resveratrol on experimental non-alcoholic steatohepatitisSara Heebøll, Karen Louise Thomsen, Andrew Clouston, et al.
Plos One|August 9, 2016
Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRITim G St Pierre, Michael J House, Sander J Bangma, et al.
Metabolism: Clinical and Experimental|September 25, 2017
Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitisMuralidhara Rao Maradana, Suman Kumar Yekollu, Bijun Zeng, et al.
British Journal of Pharmacology|June 26, 2019
Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammationZhixuan Loh, Rebecca L Fitzsimmons, Robert C Reid, et al.
Journal for Immunotherapy of Cancer|January 12, 2023
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumorsCharlotte Lemech, Keith Dredge, Darryn Bampton, et al.
Internal Medicine Journal|October 31, 2017
Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosisPreya J Patel, Xuan Banh, Leigh U Horsfall, et al.
Blood|August 5, 2010
An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammationKelli P A MacDonald, James S Palmer, Stephen Cronau, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2026
Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescenceHani Vu, Yuliangzi Sun, Zherui Xiong, et al.
Journal of Hepatology|October 10, 2025
Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trialsCarolin Lackner, Annette S H Gouw, Venancio Avancini Ferreira Alves, et al.
Carcinogenesis|February 25, 2016
Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinomaLutz Krause, Katia Nones, Kelly A Loffler, et al.
Pageof 4